Cantargia’s CAN10 demonstrates positive activity in systemic sclerosis models in new data presented at ACR Convergence 2022
Strongly supports therapeutic potential in one of CAN10’s lead indications Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new preclinical data demonstrating positive effects of the IL1RAP-binding antibody CAN10 in three different in vivo models of systemic sclerosis, a lead indication for the drug candidate. Across the models, which mimic difficult-to-treat forms of the disease, CAN10 reduced both pathological inflammation and fibrosis in skin and lung tissue, factors associated with clinical severity in humans. CAN10 also normalized a number of biomarkers closely